Compare Hasbro, Inc. (HAS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Hasbro, Inc. trades at $96.33 (market cap $13.69B), while State Street SPDR S&P Biotech ETF trades at $159.29. The key difference: Hasbro, Inc. pays a 2.89% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hasbro, Inc. nearer its low. Which is the better fit depends on your goals.
| HAS | XBI | |
|---|---|---|
Market Cap | $13.69B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $105.88 | $164.28 |
52-Week Low | $70.95 | $86.92 |
Enterprise Value | $15.88B | — |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.49, up 1.04% today, with strong technical and fundamental momentum. The stock exhibits a bullish trend, supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Recent news highlights growth in adult-focused segments like Magic: The Gathering, with Q2 2026 revenue up 16% year-over-year. Valuation metrics show a P/E of 17.27 and P/S of 2.77, while analyst consensus is bullish with a $104.90 price target.
The outlook for Hasbro is positive, driven by IP strength and digital gaming growth, but risks include margin pressures from tariffs and high debt levels. Institutional buying and a 51.52% buy rating from analysts support upside potential, though investors should monitor execution risks and macroeconomic headwinds. The stock's current price is within 5% of its 52-week high, indicating strong near-term momentum.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
